Company Name: Tianjin Zhongsheng Glory Technology Co., Ltd.（A subsidiary of Tianjin Speerise Challenge Biotechnology Co.,Ltd.
Address: N0.16 Huiyuan Rd, Zhangjiawo Industrial Park,Xiqing District, Tianjin,P.R China.
We specialize in overseas marketing of all products produced by Group Company. Main products: Veterinary Medicine & APIs, Feed & Feed additives,Pet medicine, Veterinary equipment.
Our Factory: Tianjin Speerise Challenge Biotechnology Co.,Ltd.
Our company values innovation. We have a nearly 100-person R&D team with a complete range of disciplines and a solid foundation of expertise. With independent research, development, analysis and testing, clinical trials and other comprehensive research capabilities. Over the years, it has established cooperative relationships with several domestic research institutes and has hired several well-known domestic experts and scholars as R&D consultants.The company's R&D expenditure accounts for 6-8% of sales each year. It has successively established "Tianjin Animal Biochemical Pharmaceutical Technology Engineering Center" and "Tianjin Enterprise Technology Center", "Tianjin Academician Expert Work Station", and "Tianjin Xiqing District Postdoctoral Innovation and Practice Base." The company has obtained multiple new veterinary drug certificates through independent research including ceftiofur hydrochloride injection, doxycycline hydrochloride injection, 20% enrofloxacin injection, Type-I duck hepatitis virus purified egg yolk antibody, gosling yolk purified egg yolk antibody, diclofenac sodium injection, rifaximin breast Injector. In addition, new veterinary drugs such as Gamithromycin, Tildipirosin, Tulathromycin, Altrenogest, Duck Short Beak Dwarfism Syndrome Vaccine, Duck Tembusu virus Vaccine , Porcine circovirus type 3 inactivated vaccin are under apply or review.At present, the company has applied for 48 patents, including 39 invention patents and 18 issued Patents. It has obvious advantages in high concentration sustained-release injections, drug-coated extended release technology, solubilization technique of poorly soluble drugs, high bioavailability of conventional preparations, and high stability of conventional preparations. A breakthrough has been made in the study of cross-species egg yolk antibodies, and egg yolk antibody serial products for swine and fur animals, aquatic products, bees and silkworms have been successfully developed.
Current Good manufactoring Practices(GMP)
